KAN 003
Alternative Names: KAN-003Latest Information Update: 02 Aug 2024
At a glance
- Originator Kanvas Biosciences
- Developer Kanvas Biosciences; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Bacteria
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer